ATA10002000A - Antigene zusammensetzung - Google Patents

Antigene zusammensetzung

Info

Publication number
ATA10002000A
ATA10002000A AT0100000A AT10002000A ATA10002000A AT A10002000 A ATA10002000 A AT A10002000A AT 0100000 A AT0100000 A AT 0100000A AT 10002000 A AT10002000 A AT 10002000A AT A10002000 A ATA10002000 A AT A10002000A
Authority
AT
Austria
Prior art keywords
composition
antique
inosin
cytosin
vaccine
Prior art date
Application number
AT0100000A
Other languages
English (en)
Other versions
AT410173B (de
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0100000A priority Critical patent/AT410173B/de
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to US10/297,497 priority patent/US7148191B2/en
Priority to PCT/EP2001/006433 priority patent/WO2001093905A1/en
Priority to KR20027016711A priority patent/KR100799788B1/ko
Priority to DE2001600814 priority patent/DE60100814T2/de
Priority to PT01960277T priority patent/PT1296713E/pt
Priority to BRPI0111639A priority patent/BRPI0111639B8/pt
Priority to EP20010960277 priority patent/EP1296713B1/de
Priority to CZ2002-4168A priority patent/CZ304195B6/cs
Priority to SK1815-2002A priority patent/SK287689B6/sk
Priority to US10/297,555 priority patent/US8568742B2/en
Priority to RU2003100409A priority patent/RU2293573C2/ru
Priority to CA2411575A priority patent/CA2411575C/en
Priority to TR200302015T priority patent/TR200302015T4/xx
Priority to AT01960277T priority patent/ATE249839T1/de
Priority to SI200130047T priority patent/SI1296713T1/xx
Priority to AU8181201A priority patent/AU8181201A/xx
Priority to DK01960277T priority patent/DK1296713T3/da
Priority to AU2001281812A priority patent/AU2001281812B2/en
Priority to HU0301229A priority patent/HU228264B1/hu
Priority to IL15295901A priority patent/IL152959A0/xx
Priority to CNB018107974A priority patent/CN1309418C/zh
Priority to RU2007103151A priority patent/RU2413520C2/ru
Priority to AT01936440T priority patent/ATE290880T1/de
Priority to EP01936440A priority patent/EP1286695B1/de
Priority to PCT/EP2001/006437 priority patent/WO2001093903A1/en
Priority to DE60109443T priority patent/DE60109443T2/de
Priority to ES01960277T priority patent/ES2206424T3/es
Priority to AU2001262345A priority patent/AU2001262345A1/en
Priority to PL358982A priority patent/PL211036B1/pl
Priority to MXPA02012010A priority patent/MXPA02012010A/es
Priority to HK03109011.3A priority patent/HK1056678B/xx
Priority to JP2002501476A priority patent/JP5271471B2/ja
Publication of ATA10002000A publication Critical patent/ATA10002000A/de
Priority to IS6627A priority patent/IS1993B/is
Priority to IL152959A priority patent/IL152959A/en
Priority to ZA200209479A priority patent/ZA200209479B/en
Priority to NO20025835A priority patent/NO329492B1/no
Application granted granted Critical
Publication of AT410173B publication Critical patent/AT410173B/de
Priority to US11/609,777 priority patent/US20070218073A1/en
Priority to JP2013002571A priority patent/JP5908851B2/ja
Priority to US13/786,815 priority patent/US8945591B2/en
Priority to US14/585,740 priority patent/US9492537B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0100000A 2000-06-08 2000-06-08 Antigene zusammensetzung AT410173B (de)

Priority Applications (41)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
CNB018107974A CN1309418C (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
KR20027016711A KR100799788B1 (ko) 2000-06-08 2001-06-07 면역촉진성 올리고디옥시뉴클레오티드
DE2001600814 DE60100814T2 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
PT01960277T PT1296713E (pt) 2000-06-08 2001-06-07 Oligodesoxinucleotidos imunoestimuladores
BRPI0111639A BRPI0111639B8 (pt) 2000-06-08 2001-06-07 uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
EP20010960277 EP1296713B1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
CZ2002-4168A CZ304195B6 (cs) 2000-06-08 2001-06-07 Imunostimulační farmaceutický přípravek
SK1815-2002A SK287689B6 (sk) 2000-06-08 2001-06-07 Použitie molekuly oligodeoxynukleovej kyseliny na výrobu imunostimulačnej farmaceutickej kompozície a farmaceutický prípravok
US10/297,555 US8568742B2 (en) 2000-06-08 2001-06-07 Methods and compositions involving immunostimulatory oligodeoxynucleotides
RU2003100409A RU2293573C2 (ru) 2000-06-08 2001-06-07 Иммуностимулирующие олигодезоксинуклеотиды
CA2411575A CA2411575C (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
TR200302015T TR200302015T4 (tr) 2000-06-08 2001-06-07 İmüno-uyarıcı oligodeoksinükleotitler
AT01960277T ATE249839T1 (de) 2000-06-08 2001-06-07 Immunstimulierende oligodeoxynukleotide
SI200130047T SI1296713T1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
AU8181201A AU8181201A (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
DK01960277T DK1296713T3 (da) 2000-06-08 2001-06-07 Immunstimulerende oligodeoxynukleotider
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
HU0301229A HU228264B1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
IL15295901A IL152959A0 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
US10/297,497 US7148191B2 (en) 2000-06-08 2001-06-07 Antigenic composition
AU2001281812A AU2001281812B2 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
PCT/EP2001/006433 WO2001093905A1 (en) 2000-06-08 2001-06-07 Immunostimulatory oligodeoxynucleotides
EP01936440A EP1286695B1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
PCT/EP2001/006437 WO2001093903A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
DE60109443T DE60109443T2 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
ES01960277T ES2206424T3 (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
AU2001262345A AU2001262345A1 (en) 2000-06-08 2001-06-07 Antigenic composition comprising a polycationic peptide and inosine and cytosine
PL358982A PL211036B1 (pl) 2000-06-08 2001-06-07 Zastosowanie cząsteczki immunostymulującego kwasu oligodezoksynukleinowego (ODN) i zawierająca ją kompozycja
MXPA02012010A MXPA02012010A (es) 2000-06-08 2001-06-07 Oligodesoxinucleotidos inmunoestimulantes.
HK03109011.3A HK1056678B (zh) 2000-06-08 2001-06-07 免疫刺激性寡脱氧核苷酸
JP2002501476A JP5271471B2 (ja) 2000-06-08 2001-06-07 免疫促進性オリゴデオキシヌクレオチド
RU2007103151A RU2413520C2 (ru) 2000-06-08 2001-06-07 Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды
IS6627A IS1993B (is) 2000-06-08 2002-11-18 Ónæmisörvandi fádeoxýkirni
IL152959A IL152959A (en) 2000-06-08 2002-11-20 Use of immunostimulatory oligodeoxynucleotides for the preparation of immunostimulatory pharmaceutical compositions
ZA200209479A ZA200209479B (en) 2000-06-08 2002-11-21 Immunostimulatory oligodeoxynucleotides.
NO20025835A NO329492B1 (no) 2000-06-08 2002-12-04 Anvendelse av immunstimulerende oligodeoksynukleinsyremolekyler for fremstilling av immunstimulerende, farmasoytiske sammensetninger og farmasoytiske sammensetninger som inneholder de samme.
US11/609,777 US20070218073A1 (en) 2000-06-08 2006-12-12 Antigenic composition
JP2013002571A JP5908851B2 (ja) 2000-06-08 2013-01-10 免疫促進性オリゴデオキシヌクレオチド
US13/786,815 US8945591B2 (en) 2000-06-08 2013-03-06 Methods and compositions involving immunostimulatory oligodeoxynucleotides
US14/585,740 US9492537B2 (en) 2000-06-08 2014-12-30 Methods and compositions involving immunostimulatory oligodeoxynucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung

Publications (2)

Publication Number Publication Date
ATA10002000A true ATA10002000A (de) 2002-07-15
AT410173B AT410173B (de) 2003-02-25

Family

ID=3683921

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0100000A AT410173B (de) 2000-06-08 2000-06-08 Antigene zusammensetzung
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01936440T ATE290880T1 (de) 2000-06-08 2001-06-07 Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält

Country Status (7)

Country Link
US (2) US7148191B2 (de)
EP (1) EP1286695B1 (de)
AT (2) AT410173B (de)
AU (1) AU2001262345A1 (de)
DE (1) DE60109443T2 (de)
WO (1) WO2001093903A1 (de)
ZA (1) ZA200209479B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1240331B1 (de) * 1999-12-22 2010-04-07 Aventis Pasteur Limited Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
HU228264B1 (en) 2000-06-08 2013-02-28 Intercell Ag Immunostimulatory oligodeoxynucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2002069369A2 (en) * 2000-12-08 2002-09-06 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
DK1353689T3 (da) * 2001-01-03 2006-07-31 Epitopix Llc Immuniseringspræparater og anvendelse deraf
EP1347775B1 (de) 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1483575A2 (de) * 2002-02-28 2004-12-08 Intercell AG Verfahren zur isolierung von liganden z.b. t zell epitopen
WO2003090685A2 (en) * 2002-04-24 2003-11-06 The Regents Of The University Of California Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses
EP1778186B1 (de) * 2002-07-03 2011-11-30 Oncovir, Inc. Verfahren zur herstellung von poly-iclc und seine verwendung
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
AU2003297317A1 (en) * 2002-12-13 2004-07-09 Case Western Reserve University Defensin-inducing peptides from fusobacterium
CN1756843B (zh) 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
EP1629005A2 (de) 2003-05-30 2006-03-01 Intercell AG Antigene aus enterococcus
US8329192B2 (en) 2003-09-19 2012-12-11 Epitopix Llc Campylobacter polypeptides and methods of use
WO2006045677A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
NZ597997A (en) 2005-02-14 2013-10-25 Epitopix Llc Antibody compositions that bind polypeptides from staphylococcus aureus
KR20090024292A (ko) 2006-06-28 2009-03-06 스태튼스 세룸 인스티튜트 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 ｔ세포 레퍼토리 확장
EP2292647A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2289906A1 (de) 2006-09-15 2011-03-02 Intercell AG Borrelia-Antigene
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CN101687900A (zh) * 2007-03-07 2010-03-31 恩文塔生物制药公司 双链锁核酸组合物
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2158211B1 (de) 2007-05-31 2016-08-10 Medigene AG Mutiertes strukturprotein eines parvovirus
EP2012122A1 (de) 2007-07-06 2009-01-07 Medigene AG Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2511291A3 (de) 2007-06-18 2012-11-07 Intercell AG Chlamydia-Antigene
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20110038888A1 (en) * 2008-01-10 2011-02-17 Peter Emtage Adjuvant compositions comprising poly-ic and a cationic polymer
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
NZ614557A (en) 2009-03-23 2015-03-27 Epitopix Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
PH12012500564A1 (en) 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
EP2308896A1 (de) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2319871A1 (de) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
KR20200039025A (ko) 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
MX391930B (es) 2015-01-16 2025-03-21 Zoetis Services Llc Vacuna contra la fiebre aftosa.
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3527223A1 (de) 2018-02-16 2019-08-21 2A Pharma AB Mutiertes parvovirus-strukturprotein
CN112074295A (zh) 2018-02-16 2020-12-11 2A制药公司 用于治疗自身免疫性疾病的细小病毒结构蛋白
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
WO2020240268A1 (en) 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6801650D0 (pt) * 1968-08-20 1973-03-07 R Maes Processo para preparacao de complexos geradores de interferon
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
CA2261892A1 (en) * 1996-07-24 1998-01-29 Michelle M. Hanna Base-protected nucleotide analogs with protected thiol groups
EP1272215B1 (de) * 2000-04-14 2007-10-10 Intercell AG Modifizierte peptide enthaltende pharmazeutische präparationen
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung

Also Published As

Publication number Publication date
AT410173B (de) 2003-02-25
ZA200209479B (en) 2003-11-21
US20070218073A1 (en) 2007-09-20
US20030162738A1 (en) 2003-08-28
US7148191B2 (en) 2006-12-12
DE60109443T2 (de) 2006-04-13
DE60109443D1 (de) 2005-04-21
ATE290880T1 (de) 2005-04-15
EP1286695A1 (de) 2003-03-05
EP1286695B1 (de) 2005-03-16
WO2001093903A1 (en) 2001-12-13
AU2001262345A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
DE60109443D1 (de) Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält
DE60144145D1 (de) Subtilisin-variante
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1255826T3 (da) Automatisering af proteindesign for proteinbiblioteker
ATE380822T1 (de) Funf-helix protein
AU2001291687A1 (en) Polyammonium-polysiloxane compounds, methods for the production and use thereof
PT1242121E (pt) Composicoes polipeptidicas com estabilidade melhorada
ATE384119T1 (de) Isoprenoidproduktion
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
ATE321853T1 (de) Humanische pellino-polypeptide
WO1999004011A3 (en) Hiv-1 group o antigens and uses thereof
EP1279677A4 (de) Gd3 mimetische peptide(05.11.01)
DE60221805D1 (de) Peptide mit affinität zu gp120, und ihre verwendungen
ATE342511T1 (de) Methode zur in vivo identifizierung von intrazellularen epitopen
TW200505943A (en) Polypeptide
DE60113596D1 (de) Gasreformer zur Rückgewinnung von Wasserstoff
WO2005072766A3 (en) Peptides that bind to hsp90 proteins
DE50109166D1 (de) Verfahren zur verbesserung der transfektionseffizienz
Madine The stress timebomb

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee